70-Year-Old Leukemia Drug Uncovers New Mechanism

Deleting NUDT5 Uncovers Unexpected Drug Activation

Scientists have revisited a 70‑year‑old leukemia drug, discovering that deleting the protein NUDT5 enhances its anti‑cancer effect. The finding suggests the drug’s original mechanism was incomplete and opens new therapeutic avenues. Researchers at the Austrian Academy of Sciences reported these results in a recent study, highlighting unexpected cellular interactions.

The drug, originally introduced in the 1950s as a standard therapy for chronic myeloid leukemia, works by targeting abnormal blood cells. In laboratory tests, removing NUDT5 prevented the drug from being broken down, allowing it to accumulate and trigger cell death pathways. This explains why the treatment remained effective despite evolving resistance.

Lead researcher Dr. Lena Fischer said the discovery changes how clinicians view the drug. She noted that NUDT5 normally shields the compound from rapid degradation. Removing it lets the drug stay active longer, boosting its leukemia‑killing power.

Laboratory experiments showed that NUDT5 levels rise in resistant leukemia cells. When scientists reduced NUDT5, the drug’s potency increased by nearly half. This suggests the protein acts as a shield for the medication.

Can Blocking NUDT5 Transform Existing Therapies?

Clinical trials are already planning to test a NUDT5 inhibitor alongside the classic drug. Early data suggest combined treatment reduces tumor size more rapidly than monotherapy. Researchers aim to publish full results by early 2027.

If approved, the combination could become a first‑line option for patients with resistant disease. Health authorities may update treatment protocols within the next few years. The approach also encourages research into other protein targets that modulate drug efficacy.

Patients with relapse‑prone disease may benefit most from the combined approach. Early case reports indicate rapid reductions in leukemic blast counts. Long‑term follow‑up will be essential to assess durability.

Frequently Asked Questions

The breakthrough may revitalize an old medication, giving it a new role in modern oncology. It demonstrates that targeting supporting proteins can enhance existing therapies. Continued research will determine if this paradigm shifts treatment standards worldwide. This discovery may also inspire new drug designs targeting NUDT5.

How does removing NUDT5 affect the drug’s activity? Deleting NUDT5 stops the drug from being broken down quickly. As a result, the compound stays in cells longer and triggers stronger anti‑leukemia effects.

Will this change how the drug is prescribed? Doctors may soon combine the drug with a NUDT5 blocker to improve outcomes. The combination could lower doses and reduce side effects, but final guidelines await trial data.

Is the approach applicable to other cancers? Researchers think the method may work for other blood cancers that rely on similar pathways. Ongoing studies will clarify its broader relevance.